Avita Medical Cohealyx-I Study Shows Nearly 20-Day Reduction in Skin Grafting Time
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy RCEL?
Avita Medical announced interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting for patients with full-thickness wounds. The results demonstrated statistical superiority versus a literature-derived benchmark, based on the lower bound of the 95% confidence interval. The benchmark was derived from a meta-analysis of published data on leading dermal matrices, representing approximately 900 patients. The interim analysis of 40 patients showed a median time to grafting of 11 days. Grafting was achieved as early as five days, with 25% grafted within seven days, and 72% grafted within 14 days. Investigators reported 90% satisfaction at the time of grafting, including among predominantly first-time users, supporting consistent performance and potential for broader adoption in clinical practice.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCEL
Wall Street analysts forecast RCEL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.110
Low
3.00
Averages
4.25
High
5.50
Current: 4.110
Low
3.00
Averages
4.25
High
5.50
About RCEL
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AVITA MEDICAL INC APPOINTS CARY VANCE AS CEO
Leadership Announcement: Avita Medical has appointed Cary Vance as the new Chief Executive Officer.
Company Overview: Avita Medical is focused on developing innovative regenerative medicine solutions.
See More
AVITA Medical Appoints Cary Vance as CEO Following Interim Role
- Leadership Change: AVITA Medical has appointed Cary Vance as CEO, effective immediately, after serving in an interim capacity since October 2025, indicating the board's commitment to stable leadership during a critical growth phase.
- Board Restructuring: Concurrently, Jan Stern Reed has been named chair of the board, reflecting an enhancement in the company's governance structure aimed at improving decision-making efficiency and strategic execution.
- Market Focus: Vance emphasized that the company will concentrate on scaling the adoption of its products and driving consistent performance in the acute wound care market, highlighting AVITA's strategic intent in a rapidly growing healthcare sector.
- Contract Win: AVITA Medical recently secured a BARDA contract worth up to $25.5 million, which not only provides financial backing but may also accelerate the promotion and application of its products in the market.
See More
Investigation Launched into AVITA Medical for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating AVITA Medical and its executives for potential securities fraud, advising investors to reach out for more information, which could lead to legal liabilities and impact the company's stock price.
- Declining Financial Performance: In Q2 2025, AVITA Medical disclosed that a backlog of unpaid provider claims severely hampered demand for its ReCell product, with management indicating that this issue directly affected the company's revenue and market credibility.
- Stock Price Plunge: Following the news on August 8, 2025, AVITA Medical's stock price fell by 21% to close at $4.15 per share, reflecting market concerns regarding the company's financial health and operational stability.
- Reimbursement Challenges: Management noted that contractors from the Centers for Medicare & Medicaid Services failed to adjudicate claims timely, leading to a lack of reimbursement guarantees for medical professionals using ReCell, which adversely affected the company's market performance and future growth potential.
See More
AVITA Founder Receives Lifetime Achievement Award
- Lifetime Achievement Award: Professor Fiona Wood, founder of AVITA Medical, has been awarded the Lifetime Achievement Award by the American Burn Association, recognizing her outstanding contributions to burn care, research, and education, highlighting her profound impact on modern burn care.
- Innovative Technology: The RECELL® Spray-On Skin technology developed by Professor Wood significantly enhances the healing process for burn patients by reducing donor skin requirements and improving clinical outcomes, driving advancements in global burn care.
- Industry Leadership: With over three decades of leadership in burn care, Professor Wood serves as the Director of the Burns Service of Western Australia, influencing clinical practices worldwide and laying the groundwork for future burn treatments.
- Global Recognition: Professor Wood's achievements have gained international recognition, including the Officer of the Order of Australia and Australian of the Year in 2005, with her research reflected in hundreds of scientific publications, further advancing burn care globally.
See More
AVITA Medical's Cohealyx Accelerates Skin Grafting Time
- Product Performance Improvement: AVITA Medical's Cohealyx product demonstrates remarkable efficacy in wound care, reducing skin grafting time from a benchmark of 33.2 days to 13.6 days, indicating a significant clinical advantage that could redefine wound preparation standards.
- Clinical Trial Results: The Cohealyx-I multi-center study analysis of 40 patients shows a median grafting time of 11 days, with 75% of grafts occurring within 14 days, further validating the product's effectiveness and rapid response capabilities.
- Market Potential: The release of this data led to a ~15% increase in AVITA Medical's stock price on Tuesday, reflecting market optimism regarding the product's prospects and potentially driving the company's market share growth in wound care.
- Future Outlook: AVITA's interim CEO Cary Vance noted that this data strengthens their belief that Cohealyx can set a new benchmark in wound bed preparation, with full clinical data expected to be released this year to further support product marketing.
See More
AVITA Medical Secures Up to $25.5M Deal with BARDA for RECELL Supply
- Significant Agreement Value: AVITA Medical's deal with the Biomedical Advanced Research and Development Authority (BARDA) is valued at up to $25.5 million, aimed at enhancing U.S. readiness for mass burn casualty incidents, highlighting the company's importance and potential in the medical field.
- Product Delivery Plan: Under the 10-year agreement, BARDA will accept delivery of 3,000 units of RECELL, allowing AVITA to promote its leading product across the U.S., thereby enhancing the company's influence in the wound care market.
- Clear Revenue Expectations: AVITA anticipates recognizing $3.97 million in revenue over the next decade, primarily from annual access-maintenance fees and readiness support, which provides financial stability and lays a foundation for future growth.
- Optimistic Market Outlook: AVITA Medical has set a revenue target of $80 million to $85 million for 2026, with reimbursement clarity expected to drive multi-product utilization, further strengthening the company's market competitiveness and profitability.
See More
AVITA MEDICAL INC APPOINTS CARY VANCE AS CEO
Leadership Announcement: Avita Medical has appointed Cary Vance as the new Chief Executive Officer.
Company Overview: Avita Medical is focused on developing innovative regenerative medicine solutions.
See More
AVITA Medical Appoints Cary Vance as CEO Following Interim Role
- Leadership Change: AVITA Medical has appointed Cary Vance as CEO, effective immediately, after serving in an interim capacity since October 2025, indicating the board's commitment to stable leadership during a critical growth phase.
- Board Restructuring: Concurrently, Jan Stern Reed has been named chair of the board, reflecting an enhancement in the company's governance structure aimed at improving decision-making efficiency and strategic execution.
- Market Focus: Vance emphasized that the company will concentrate on scaling the adoption of its products and driving consistent performance in the acute wound care market, highlighting AVITA's strategic intent in a rapidly growing healthcare sector.
- Contract Win: AVITA Medical recently secured a BARDA contract worth up to $25.5 million, which not only provides financial backing but may also accelerate the promotion and application of its products in the market.
See More
Investigation Launched into AVITA Medical for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating AVITA Medical and its executives for potential securities fraud, advising investors to reach out for more information, which could lead to legal liabilities and impact the company's stock price.
- Declining Financial Performance: In Q2 2025, AVITA Medical disclosed that a backlog of unpaid provider claims severely hampered demand for its ReCell product, with management indicating that this issue directly affected the company's revenue and market credibility.
- Stock Price Plunge: Following the news on August 8, 2025, AVITA Medical's stock price fell by 21% to close at $4.15 per share, reflecting market concerns regarding the company's financial health and operational stability.
- Reimbursement Challenges: Management noted that contractors from the Centers for Medicare & Medicaid Services failed to adjudicate claims timely, leading to a lack of reimbursement guarantees for medical professionals using ReCell, which adversely affected the company's market performance and future growth potential.
See More
AVITA Founder Receives Lifetime Achievement Award
- Lifetime Achievement Award: Professor Fiona Wood, founder of AVITA Medical, has been awarded the Lifetime Achievement Award by the American Burn Association, recognizing her outstanding contributions to burn care, research, and education, highlighting her profound impact on modern burn care.
- Innovative Technology: The RECELL® Spray-On Skin technology developed by Professor Wood significantly enhances the healing process for burn patients by reducing donor skin requirements and improving clinical outcomes, driving advancements in global burn care.
- Industry Leadership: With over three decades of leadership in burn care, Professor Wood serves as the Director of the Burns Service of Western Australia, influencing clinical practices worldwide and laying the groundwork for future burn treatments.
- Global Recognition: Professor Wood's achievements have gained international recognition, including the Officer of the Order of Australia and Australian of the Year in 2005, with her research reflected in hundreds of scientific publications, further advancing burn care globally.
See More
AVITA Medical's Cohealyx Accelerates Skin Grafting Time
- Product Performance Improvement: AVITA Medical's Cohealyx product demonstrates remarkable efficacy in wound care, reducing skin grafting time from a benchmark of 33.2 days to 13.6 days, indicating a significant clinical advantage that could redefine wound preparation standards.
- Clinical Trial Results: The Cohealyx-I multi-center study analysis of 40 patients shows a median grafting time of 11 days, with 75% of grafts occurring within 14 days, further validating the product's effectiveness and rapid response capabilities.
- Market Potential: The release of this data led to a ~15% increase in AVITA Medical's stock price on Tuesday, reflecting market optimism regarding the product's prospects and potentially driving the company's market share growth in wound care.
- Future Outlook: AVITA's interim CEO Cary Vance noted that this data strengthens their belief that Cohealyx can set a new benchmark in wound bed preparation, with full clinical data expected to be released this year to further support product marketing.
See More
AVITA Medical Secures Up to $25.5M Deal with BARDA for RECELL Supply
- Significant Agreement Value: AVITA Medical's deal with the Biomedical Advanced Research and Development Authority (BARDA) is valued at up to $25.5 million, aimed at enhancing U.S. readiness for mass burn casualty incidents, highlighting the company's importance and potential in the medical field.
- Product Delivery Plan: Under the 10-year agreement, BARDA will accept delivery of 3,000 units of RECELL, allowing AVITA to promote its leading product across the U.S., thereby enhancing the company's influence in the wound care market.
- Clear Revenue Expectations: AVITA anticipates recognizing $3.97 million in revenue over the next decade, primarily from annual access-maintenance fees and readiness support, which provides financial stability and lays a foundation for future growth.
- Optimistic Market Outlook: AVITA Medical has set a revenue target of $80 million to $85 million for 2026, with reimbursement clarity expected to drive multi-product utilization, further strengthening the company's market competitiveness and profitability.
See More
